These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 6094274)

  • 1. [The effects of o,p'-DDD on human adrenal steroid synthesis].
    Ojima M; Saito M; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):852-71. PubMed ID: 6094274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of o,p'-DDD on pituitary-gonadal function in patients with Cushing's disease].
    Ojima M; Hashimoto S; Itoh N; Kusano Y; Satoh K; Egawa M; Gomibuchi T; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1988 Jun; 64(6):451-62. PubMed ID: 3145221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma.
    Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A
    Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of o,p'-DDD on cortisol metabolism in Cushing's syndrome of various etiology.
    Koide Y; Inoue S; Murayama H; Kawai K; Yamashita K
    Endocrinol Jpn; 1985 Oct; 32(5):615-24. PubMed ID: 3004927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
    Touitou Y; Moolenaar AJ; Bogdan A; Auzéby A; Luton JP
    Eur J Clin Pharmacol; 1985; 29(4):483-7. PubMed ID: 4092727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid content of the peripheral and adrenal vein in Cushing's syndrome due to adrenocortical adenoma and carcinoma.
    Levine AC; Mitty HA; Gabrilove JL
    J Urol; 1988 Jul; 140(1):11-5. PubMed ID: 2967899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.
    Benecke R; Keller E; Vetter B; de Zeeuw RA
    Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effects of o,p'-DDD on adrenal steroidogenesis and hepatic steroid metabolism].
    Ojima M; Saitoh M; Itoh N; Kusano Y; Fukuchi S; Naganuma H
    Nihon Naibunpi Gakkai Zasshi; 1985 Mar; 61(3):168-78. PubMed ID: 3874792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase.
    Engelhardt D; Dörr G; Jaspers C; Knorr D
    Klin Wochenschr; 1985 Jul; 63(13):607-12. PubMed ID: 2993735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of adrenal function after treatment of adrenocortical carcinoma with o,p'-DDD.
    Greig F; Oberfield SE; Levine LS; Ghavimi F; Pang S; New MI
    Clin Endocrinol (Oxf); 1984 Apr; 20(4):389-99. PubMed ID: 6325050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple-sites of inhibition by intravenous metyrapone of human adrenal steroidogenesis.
    Schöneshöfer M; Claus M
    Acta Endocrinol (Copenh); 1985 Jul; 109(3):378-85. PubMed ID: 2992206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of o,p'-DDD on plasma ACTH concentration in Cushing's disease.
    Bruno OD; Hoschoian JC; Andrada JA
    Medicina (B Aires); 1979; 39(2):229-34. PubMed ID: 228150
    [No Abstract]   [Full Text] [Related]  

  • 13. [Plasma steroid hormones in Cushing's syndrome: their relation to cause and clinical manifestations (author's transl)].
    Horio S; Funahashi H; Mizuno S
    Nihon Naibunpi Gakkai Zasshi; 1981 May; 57(5):807-25. PubMed ID: 7286345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Corticosteroid synthesis in chicken adrenals as affected by o,p'-DDD].
    Kravchenko VI
    Ukr Biokhim Zh (1978); 1978; 50(2):180-3. PubMed ID: 307291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo.
    Leiba S; Weinstein R; Shindel B; Lapidot M; Stern E; Levavi H; Rusecki Y; Abramovici A
    Ann Endocrinol (Paris); 1989; 50(1):49-53. PubMed ID: 2729882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o,p'-DDD for Cushing's syndrome: evidence for the sites of action of the drug.
    Touitou Y; Bogdan A; Luton JP
    J Steroid Biochem; 1978 Dec; 9(12):1217-24. PubMed ID: 745418
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of Cushing's disease with o,p'-DDD followed by pituitary irradiation in a 19-year-old male patient.
    Dickerman Z; Kaufman H; Laron Z
    Isr J Med Sci; 1979 May; 15(5):455-9. PubMed ID: 447515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma 19-hydroxyandrostenedione levels in Cushing's disease: stimulation with ACTH and inhibition with metyrapone.
    Mune T; Morita H; Yasuda K; Murayama M; Yamakita N; Miura K
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):265-72. PubMed ID: 8384536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of adrenocortical tumour.
    Flecchia D; Mazza E; Carlini M; Blatto A; Olivieri F; Serra G; Camanni F; Messina M
    Clin Endocrinol (Oxf); 1995 Feb; 42(2):129-34. PubMed ID: 7704956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of dissociation of cortisol and adrenal androgen secretion after removal of adrenocortical adenoma in patients with Cushing's syndrome.
    Nawata H; Higuchi K; Yanase T; Takayanagi R; Kato K; Ibayashi H
    Endocrinol Jpn; 1985 Oct; 32(5):691-700. PubMed ID: 2936600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.